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Health economics studies assessing irbesartan use in patients
with hypertension, type 2 diabetes, and microalbuminuria. Two
studies comparing the cost-effectiveness of irbesartan to similar
blood pressure control with standard antihypertensive medica-
tions (excluding angiotensin-converting enzyme inhibitors and
other angiotensin receptor blockers) in treatment of patients
with hypertension, type 2 diabetes, and microalbuminuria have
been published to date; one in a United States setting, the other
in a Spanish setting. Both studies were based on a Markov-based
Monte Carlo simulation model, with the effects of irbesartan or
standard blood pressure control taken from the Irbesartan Re-
duction of Microalbuminuria-2 (IRMA-2) and the Irbesartan
in Diabetic Nephropathy Trial (IDNT) clinical trials. In both
Spanish and U.S. settings, irbesartan was projected to delay the
onset of end-stage renal disease (ESRD), reduce the cumula-
tive incidence of ESRD, increase life expectancy, and reduce
overall direct medical costs. Irbesartan treatment of patients
with type 2 diabetes, hypertension, and microalbuminuria may
lead to major improvements in long-term patient outcomes,
with substantial cost savings as an added bonus to third party
payers.
Diabetic nephropathy will develop in 30% to 40% of
patients with type 2 diabetes. It is the most common
cause of end-stage renal disease (ESRD) in Europe and
the United States [1–3]. The incidence and prevalence of
ESRD caused primarily by type 2 diabetes is increasing
in the United States and Spain [4, 5], and will further rise
with the increasing prevalence of diabetes [6]. Two clin-
ical trials have recently investigated the blood pressure–
independent renoprotective effects of the angiotensin II
receptor antagonist irbesartan on the progression of renal
disease in patients with hypertension and type 2 diabetes
[7, 8]. In the Irbesartan Reduction of Microalbuminuria-
2 (IRMA-2) study [7], the hazard ratio for progression
from microalbuminuria to overt nephropathy for irbe-
sartan 300 mg daily versus placebo control (standard hy-
pertensive therapy with identical blood pressure targets)
was 0.30 (95% CI 0.14–0.61) over a two-year follow-up
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period. In the Irbesartan in Diabetic Nephropathy Trial
(IDNT) [8], treatment of hypertensive patients with type
2 diabetes and advanced overt nephropathy with irbe-
sartan resulted in a reduction of 23% in the combined
end point of death, ESRD, and doubling of serum creati-
nine (DSC) compared with amlodipine (P = 0.006), and
a 20% reduction compared with the control group (P =
0.02) over a 2.6-year mean follow-up period.
The aim of this paper was to review the current pub-
lished health economic evidence on irbesartan in the
treatment of patients with microalbuminuria, hyperten-
sion, and type 2 diabetes. Studies specifically investigating
health economic aspects of treatment of advanced overt
nephropathy were not taken into consideration.
Two health economics studies have recently been pub-
lished that investigated the cost-effectiveness of treat-
ing patients with type 2 diabetes, hypertension, and
microalbuminuria with either irbesartan 300 mg daily
or standard blood pressure control, which included stan-
dard antihypertensive medications as required to achieve
a target blood pressure of <135/85 mm Hg [excluding
angiotensin-converting enzyme (ACE) inhibitors, other
angiotensin receptor antagonists, and dihydropyridine
calcium channel blockers] [9, 10]. Both these studies
were based on a computer simulation model that used
clinical data from IRMA-2 and IDNT, as well as data
drawn from other published sources to perform cost
consequence analyses. The model used standard, well-
accepted techniques (Markov-based Monte Carlo simu-
lation) to describe the progression of patients with type
2 diabetes and hypertension through progressively wors-
ening degrees of diabetic nephropathy—from microal-
buminuria to early overt nephropathy, advanced overt
nephropathy, DSC, ESRD treated with either dialysis or
renal transplant, and death. Two treatment choices were
simulated: (1) irbesartan—irbesartan 300 mg daily plus
other adjunctive blood pressure medications (including
diuretics, beta-blockers alpha/beta blockers, peripheral
vasodilators, peripheral adrenergic blockers, and central
adrenergic blockers, but excluded ACE inhibitors, other
angiotensin receptor antagonists, and dihydropyridine
calcium channel blockers) as required to achieve a
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Fig. 1. Mean number of years per patient spent in each disease state
with either standard blood pressure control or irbesartan treatment
in the Spanish setting. MA, microalbuminuria; GPR, gross protein-
uria; DSC, doubling of serum creatinine; ESRD, end-stage renal dis-
ease. Control, standard antihypertensive medications excluding ACE
inhibitors, other angiotensin-2-receptor antagonists, and dihydropyri-
dine calcium channel blockers with equivalent blood pressure control.
Irbesartan, standard antihypertensive medications plus 300 mg irbesar-
tan daily, started when patients have microalbuminuria. Reproduced
from [10].
target blood pressure of <135/85 mm Hg; and (2)
placebo control (hereafter referred to as control)—
standard antihypertensive medications as previously de-
scribed as required to achieve the target blood pressure of
<135/85 mm Hg.
RESULTS AND DISCUSSION
Compared with control, irbesartan reduced the cumu-
lative incidence of ESRD, delayed the onset of ESRD, in-
creased life expectancy, and led to overall direct medical
cost savings in both the Spanish and United States set-
tings. Irbesartan delayed the progression from microal-
buminuria to more severe stages of diabetic renal disease.
Patients spent more years in the state of microalbumin-
uria and fewer years in early and advanced proteinuria,
DSC, or the ESRD states (where the annual risk of death
was higher than that of patients who remained in the
state of microalbuminuria) when treated with irbesartan
(Fig. 1).
The cumulative incidence of ESRD in the Spanish
setting was reduced from (mean ± standard deviation)
24% ± 1% to 9% ± 2% with irbesartan versus con-
trol, and from 20% ± 2% to 7% ± 1% in the United
States setting. Irbesartan treatment led to 321 days of
ESRD avoided in the Spanish setting, and 269 days in the
United States setting versus control. Undiscounted life
expectancy was improved from 14.78 ± 0.02 to 16.18 ±
0.26 years (an improvement of 1.40 ± 0.27 years with irbe-
sartan) in the Spanish setting, and from 13.19 ± 0.03 to
14.75 ± 0.27 years (an improvement of 1.55 ± 0.27 years)
in the United States setting. In the Spanish setting, costs
were reduced from €25,119 ± 1,742 per patient with stan-
dard hypertension treatment to €14,038±2,292 with irbe-
sartan (cost savings after 25 years of €11,082 ± 2,996 per
patient); and in the United States setting were reduced
from $28,782 ± 2,045 to $16,859 ± 2,545 (cost savings af-
ter 25 years of $11,922 ± 3,250 per patient). Cost savings
became evident after 8 to 10 years with irbesartan treat-
ment versus control (Fig. 2). Sensitivity analysis revealed
that conclusions were robust under a wide range of plau-
sible assumptions. Differences in projected life expectan-
cies between the two countries are due to differences in
country-specific probabilities of age- and gender-specific
annual mortality, and to differences in rates of kidney
transplantation, dialysis transfer between the two modes
of renal replacement therapy, and country-specific differ-
ences in survival rates for patients who develop ESRD.
Differences in costs between the two settings were due
to the differences in acquisition costs of medications, dif-
ferences in the costs of treating ESRD, and different life
expectancies projected in Spain and the United States.
The results of the two modeling studies published so far
in the United States and Spanish setting are consistent—
the use of irbesartan to treat patients with type 2 di-
abetes, hypertension, and microalbuminuria leads to
substantial economic savings and major improvements in
patient outcomes compared with treatment with standard
blood pressure control alone (excluding ACE inhibitors),
showing the importance of early treatment with irbesar-
tan in these patients. Both studies considered only the
direct medical costs of irbesartan and ESRD treatment.
If a societal perspective had been taken, where indirect
costs due to lost productivity secondary to absence from
work and premature death were also considered, the costs
savings expected with irbesartan would have been sub-
stantially higher.
Previous analyses based on the IDNT study demon-
strated that irbesartan treatment started at a later stage of
renal disease in patients with advanced overt nephropa-
thy, hypertension, and type 2 diabetes also leads to delay
in the onset of ESRD, improvements in life expectancy,
and cost savings due to ESRD avoided compared with
standard hypertension treatment or amlodipine in sev-
eral European countries and in the United States [11–15].
Both early use of irbesartan (in patients with microalbu-
minuria) and late intervention (in patients with advanced
overt nephropathy) were projected to lead to delay in
the onset of ESRD, subsequent improvements in life ex-
pectancy, and substantial cost savings.
CONCLUSION
Studies published to date provide supportive evidence
for the use of irbesartan in patients with type 2 diabetes,
hypertension, and microalbuminuria in both Spanish and
United States settings. Irbesartan initiated in the early
stages of diabetic nephropathy was predicted to lead to
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Fig. 2. Cost savings per treated patient, irbe-
sartan versus control in the United States set-
ting. Cost savings became evident after 9 to 10
years, and increased to a maximum of $11,922
per patient after 25 years. Modified from [9].
decreased incidence of ESRD, increased life expectancy,
and cost savings.
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